NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Eli Lilly and Company ("Eli Lilly") (NYSE:LLY) concerning possible violations of federal securities laws.
On May 1, 2025, Eli Lilly issued a press release reporting first quarter 2025 results and reaffirming guidance. In conjunction with this press release, Eli Lilly management commented on the decision made by CVS, one of the country's largest pharmacies, to drop coverage for its popular weight-loss drug, Zepbound, in favor of competitor's Wegovy. Notably, Eli Lilly's CEO attributes 45% of the Company's year-over-year revenue growth to strong sales of Zepbound and Mounjaro.
Following this news, Eli Lilly's stock price fell by $104.85 per share, or approximately 11.7% to close at $794.10 per share.
To obtain additional information, go to:
https://zlk.com/pslra-1/eli-lilly-lawsuit-submission-form?prid=147240&wire=1
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
View the original
press release on ACCESS Newswire
